Literature DB >> 22752486

Vigabatrin and mental retardation in tuberous sclerosis: infantile spasms versus focal seizures.

Mi-Sun Yum1, Eun Hye Lee, Tae-Sung Ko.   

Abstract

Tuberous sclerosis complex is a genetic disorder resulting in epilepsy and mental retardation. Vigabatrin has shown efficacy in the treatment of infantile spasms caused by tuberous sclerosis complex, but its effects on focal seizures caused by tuberous sclerosis complex have not been determined. We compared the efficacy of vigabatrin in patients with tuberous sclerosis complex-induced focal seizures and infantile spasms and assessed the mental outcomes in both groups. We retrospectively evaluated 31 children with tuberous sclerosis complex and epilepsy, who were treated with vigabatrin in a single tertiary center in Seoul, Korea. Vigabatrin treatment resulted in spasms cessation in 16 of 18 (88.9%) patients with infantile spasms, whereas 6 of 13 (46.2%) patients with focal seizures became seizure free. Initial response to vigabatrin had no effect on intellectual disability. Vigabatrin was highly effective in eliminating infantile spasms caused by tuberous sclerosis complex but was less effective in patients with focal seizures.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22752486      PMCID: PMC3695701          DOI: 10.1177/0883073812446485

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  34 in total

Review 1.  Gene expression analysis as a strategy to understand the molecular pathogenesis of infantile spasms.

Authors:  Peter B Crino
Journal:  Int Rev Neurobiol       Date:  2002       Impact factor: 3.230

2.  Epilepsy surgery in children with tuberous sclerosis complex: presurgical evaluation and outcome.

Authors:  S Koh; P Jayakar; C Dunoyer; S E Whiting; T J Resnick; L A Alvarez; G Morrison; J Ragheb; A Prats; P Dean; J Gilman; M S Duchowny
Journal:  Epilepsia       Date:  2000-09       Impact factor: 5.864

3.  Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients.

Authors:  I Jambaqué; C Chiron; C Dumas; J Mumford; O Dulac
Journal:  Epilepsy Res       Date:  2000-02       Impact factor: 3.045

4.  Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex.

Authors:  C Joinson; F J O'Callaghan; J P Osborne; C Martyn; T Harris; P F Bolton
Journal:  Psychol Med       Date:  2003-02       Impact factor: 7.723

5.  Selective alterations in glutamate and GABA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers.

Authors:  R White; Y Hua; B Scheithauer; D R Lynch; E P Henske; P B Crino
Journal:  Ann Neurol       Date:  2001-01       Impact factor: 10.422

Review 6.  Tuberous sclerosis as an underlying basis for infantile spasm.

Authors:  Raymond S Yeung
Journal:  Int Rev Neurobiol       Date:  2002       Impact factor: 3.230

7.  Randomized trial of vigabatrin in patients with infantile spasms.

Authors:  R D Elterman; W D Shields; K A Mansfield; J Nakagawa
Journal:  Neurology       Date:  2001-10-23       Impact factor: 9.910

Review 8.  Infantile spasms in tuberous sclerosis complex.

Authors:  P Curatolo; S Seri; M Verdecchia; R Bombardieri
Journal:  Brain Dev       Date:  2001-11       Impact factor: 1.961

Review 9.  Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate.

Authors:  Mikael Angehagen; Elinor Ben-Menachem; Lars Rönnbäck; Elisabeth Hansson
Journal:  Neurochem Res       Date:  2003-02       Impact factor: 3.996

Review 10.  Treatment of infantile spasms.

Authors:  E Hancock; J Osborne; P Milner
Journal:  Cochrane Database Syst Rev       Date:  2003
View more
  4 in total

Review 1.  Update on Drug Management of Refractory Epilepsy in Tuberous Sclerosis Complex.

Authors:  Emma van der Poest Clement; Floor E Jansen; Kees P J Braun; Jurriaan M Peters
Journal:  Paediatr Drugs       Date:  2020-02       Impact factor: 3.022

Review 2.  Tuberous Sclerosis: A New Frontier in Targeted Treatment of Autism.

Authors:  Peter E Davis; Jurriaan M Peters; Darcy A Krueger; Mustafa Sahin
Journal:  Neurotherapeutics       Date:  2015-07       Impact factor: 7.620

Review 3.  Modeling epileptic spasms during infancy: Are we heading for the treatment yet?

Authors:  Libor Velíšek; Jana Velíšková
Journal:  Pharmacol Ther       Date:  2020-05-15       Impact factor: 12.310

Review 4.  The research landscape of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND)-a comprehensive scoping review.

Authors:  Stephanie Vanclooster; Stacey Bissell; Agnies M van Eeghen; Nola Chambers; Liesbeth De Waele; Anna W Byars; Jamie K Capal; Sebastián Cukier; Peter Davis; Jennifer Flinn; Sugnet Gardner-Lubbe; Tanjala Gipson; Tosca-Marie Heunis; Dena Hook; J Christopher Kingswood; Darcy A Krueger; Aubrey J Kumm; Mustafa Sahin; Eva Schoeters; Catherine Smith; Shoba Srivastava; Megumi Takei; Robert Waltereit; Anna C Jansen; Petrus J de Vries
Journal:  J Neurodev Disord       Date:  2022-02-13       Impact factor: 4.025

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.